Effects of suppressing glucose transporter-1 by an antisense oligodeoxynucleotide on the growth of human hepatocellular carcinoma cells

Hepatobiliary and Pancreatic Diseases International

Volumn 10, Issue 1, 2011, Pages 72-77

  Liu, Tian Qi ^a,b,c,e   Fan, Jun ^d   Zhou, Lin ^a,b,c   Zheng, Shu Sen ^a,b,c  

^a BEIJING HOSPITAL   (China)

^b KEY LABORATORY OF ORGAN TRANSPLANTATION   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d ZHEJIANG UNIVERSITY   (China)

^e PEOPLE'S HOSPITAL OF GUANGXI ZHUANG AUTONOMOUS REGION   (China)

Author keywords

Glucose transporter 1; Hepatocellular carcinoma; HepG 2 cell; Therapeutic target

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; BETA ACTIN; GLUCOSE TRANSPORTER 1; MESSENGER RNA;

ARTICLE; CANCER GROWTH; CARCINOMA CELL; CELL STRAIN HEPG2; CONTROLLED STUDY; DNA VECTOR; DOWN REGULATION; GENETIC TRANSFECTION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 79952063750     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1499-3872(11)60010-6     Document Type: Article

References (35)

1. Amann T, Hellerbrand C. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 2009;13:1411-1427.
2. El-Serag HB. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology 2004;127:S27-34.
3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
4. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
5. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
6. Yang L, Parkin DM, Ferlay J, Li L, Chen Y. Estimates of cancer incidence in China for 2000 and projections for 2005. Cancer Epidemiol Biomarkers Prev 2005;14:243-250.
7. Rampone B, Schiavone B, Confuorto G. Current management of hepatocellular cancer. Curr Oncol Rep 2010;12:186-192.
8. Zheng SS, Xu X, Wu J, Chen J, Wang WL, Zhang M, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008;85:1726-1732.
9. Xu X, Zheng SS, Liang TB, Wang WL, Jin J, Shen Y, et al. Orthotopic liver transplantation for patients with hepatocellular carcinoma complicated by portal vein tumor thrombi. Hepatobiliary Pancreat Dis Int 2004;3:341-344. (Pubitemid 39173062)
10. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 2005;65:613-621.
11. Warburg O. On the origin of cancer cells. Science 1956;123:309-314.
12. Kim JW, Dang CV. Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006;66:8927-8930. (Pubitemid 44521105)
13. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia signalling controls metabolic demand. Curr Opin Cell Biol 2007;19:223-229. (Pubitemid 46386401)
14. Miura Y, Tsudo M. Fluorodeoxyglucose-PET/CT for diagnosis of intravascular large B-cell lymphoma. Mayo Clin Proc 2010;85:e56-57.
15. Prante O, Maschauer S, Fremont V, Reinfelder J, Stoehr R, Szkudlinski M, et al. Regulation of uptake of 18F-FDG by a follicular human thyroid cancer cell line with mutation-activated K-ras. J Nucl Med 2009;50:1364-1370.
16. Zhou S, Wang S, Wu Q, Fan J, Wang Q. Expression of glucose transporter-1 and -3 in the head and neck carcinoma - the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec 2008;70:189-194. (Pubitemid 351595115)
17. Li LF, Zhou SH, Zhao K, Wang SQ, Wu QL, Fan J, et al. Clinical significance of FDG single-photon emission computed tomography: Computed tomography in the diagnosis of head and neck cancers and study of its mechanism. Cancer Biother Radiopharm 2008;23:701-714.
18. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, et al. Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. Eur J Cardiothorac Surg 2009;35:699-705.
19. Robey IF, Stephen RM, Brown KS, Baggett BK, Gatenby RA, Gillies RJ. Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia 2008;10:745-756.
20. Demasi AP, Costa AF, Altemani A, Furuse C, Araújo NS, Araújo VC. Glucose transporter protein 1 expression in mucoepidermoid carcinoma of salivary gland: correlation with grade of malignancy. Int J Exp Pathol 2010;91:107-113.
21. Endo M, Tateishi U, Seki K, Yamaguchi U, Nakatani F, Kawai A, et al. Prognostic implications of glucose transporter protein-1 (glut-1) overexpression in bone and soft-tissue sarcomas. Jpn J Clin Oncol 2007;37:955-960. (Pubitemid 351176488)
22. Amann T, Maegdefrau U, Hartmann A, Agaimy A, Marienhagen J, Weiss TS, et al. GLUT1 expression is increased in hepatocellular carcinoma and promotes tumorigenesis. Am J Pathol 2009;174:1544-1552.
23. Zhao S, Kuge Y, Mochizuki T, Takahashi T, Nakada K, Sato M, et al. Biologic correlates of intratumoral heterogeneity in 18F-FDG distribution with regional expression of glucose transporters and hexokinase-II in experimental tumor. J Nucl Med 2005;46:675-682. (Pubitemid 41716413)
24. Paudyal B, Paudyal P, Oriuchi N, Tsushima Y, Nakajima T, Endo K. Clinical implication of glucose transport and metabolism evaluated by 18F-FDG PET in hepatocellular carcinoma. Int J Oncol 2008;33:1047-1054.
25. Zimmerman RL, Fogt F, Burke M, Murakata LA. Assessment of Glut-1 expression in cholangiocarcinoma, benign biliary lesions and hepatocellular carcinoma. Oncol Rep 2002;9:689-692.
26. Chen CP, Li XX, Zhang LR, Min JM, Chan JY, Fung KP, et al. Synthesis of antisense oligonucleotide-peptide conjugate targeting to GLUT-1 in HepG-2 and MCF-7 Cells. Bioconjug Chem 2002;13:525-529. (Pubitemid 34527514)
27. WeiXing C, Tiantian H, Qun N, Chaohui Y, Ping X. Inhibitory effect of hypoxia inducible factor-1 antisense oligonucleotide on growth of human hepatocellular carcinoma cells. Med Oncol 2008;25:88-92.
28. Noguchi Y, Saito A, Miyagi Y, Yamanaka S, Marat D, Doi C, et al. Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett 2000;154:175-182. (Pubitemid 30259224)
29. Zhou SH, Fan J, Chen XM, Cheng KJ, Wang SQ. Inhibition of cell proliferation and glucose uptake in human laryngeal carcinoma cells by antisense oligonucleotides against glucose transporter-1. Head Neck 2009;31:1624-1633.
30. Xiong Y, Xiong YY, Zhou YF. Expression and significance of beta-catenin, Glut-1 and PTEN in proliferative endometrium, endometrial intraepithelial neoplasia and endometrioid adenocarcinoma. Eur J Gynaecol Oncol 2010;31:160-164.
31. Ayala FR, Rocha RM, Carvalho KC, Carvalho AL, da Cunha IW, Lourenço SV, et al. GLUT1 and GLUT3 as potential prognostic markers for oral squamous cell carcinoma. Molecules 2010;15:2374-2387.
32. Airley R, Evans A, Mobasheri A, Hewitt SM. Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays. Ann Anat 2010;192:133-138.
33. Ito S, Fukusato T, Nemoto T, Sekihara H, Seyama Y, Kubota S. Coexpression of glucose transporter 1 and matrix metalloproteinase-2 in human cancers. J Natl Cancer Inst 2002;94:1080-1091. (Pubitemid 34830728)
34. Chan JY, Kong SK, Choy YM, Lee CY, Fung KP. Inhibition of glucose transporter gene expression by antisense nucleic acids in HL-60 leukemia cells. Life Sci 1999;65:63-70. (Pubitemid 29292806)
35. Choi JW, Yoon DJ, Lee HW, Han DP, Ahn YH. Antisense GLUT1 RNA suppresses the transforming phenotypes of NIH 3T3 cells transformed by N-Ras. Yonsei Med J 1995;36:480-486.